Savara (SVRA) Competitors $2.86 -0.07 (-2.22%) As of 12:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. LGND, HRMY, BLTE, KNSA, ARWR, GMTX, TVTX, FOLD, SUPN, and SDGRShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Ligand Pharmaceuticals (LGND), Harmony Biosciences (HRMY), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Arrowhead Pharmaceuticals (ARWR), Gemini Therapeutics (GMTX), Travere Therapeutics (TVTX), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry. Savara vs. Ligand Pharmaceuticals Harmony Biosciences Belite Bio Kiniksa Pharmaceuticals Arrowhead Pharmaceuticals Gemini Therapeutics Travere Therapeutics Amicus Therapeutics Supernus Pharmaceuticals Schrödinger Ligand Pharmaceuticals (NASDAQ:LGND) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Do institutionals & insiders have more ownership in LGND or SVRA? 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor LGND or SVRA? In the previous week, Savara had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for Savara and 4 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.33 beat Savara's score of 0.76 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer LGND or SVRA? Ligand Pharmaceuticals received 253 more outperform votes than Savara when rated by MarketBeat users. Likewise, 70.39% of users gave Ligand Pharmaceuticals an outperform vote while only 66.89% of users gave Savara an outperform vote. CompanyUnderperformOutperformLigand PharmaceuticalsOutperform Votes55470.39% Underperform Votes23329.61% SavaraOutperform Votes30166.89% Underperform Votes14933.11% Is LGND or SVRA more profitable? Ligand Pharmaceuticals has a net margin of 29.68% compared to Savara's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Ligand Pharmaceuticals29.68% 4.95% 4.39% Savara N/A -58.89%-46.44% Which has more risk & volatility, LGND or SVRA? Ligand Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Which has stronger earnings & valuation, LGND or SVRA? Ligand Pharmaceuticals has higher revenue and earnings than Savara. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLigand Pharmaceuticals$181.49M10.77$52.15M-$7.12-14.23SavaraN/AN/A-$54.70M-$0.48-6.10 Do analysts rate LGND or SVRA? Ligand Pharmaceuticals currently has a consensus target price of $146.14, suggesting a potential upside of 44.28%. Savara has a consensus target price of $8.83, suggesting a potential upside of 201.48%. Given Savara's higher probable upside, analysts clearly believe Savara is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryLigand Pharmaceuticals beats Savara on 14 of the 17 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$506.41M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-6.819.0626.8019.71Price / SalesN/A251.66397.78120.67Price / CashN/A65.8538.2534.62Price / Book2.826.456.774.50Net Income-$54.70M$143.98M$3.23B$248.22M7 Day Performance-4.56%0.38%0.48%-0.78%1 Month Performance-9.85%2.14%9.13%11.53%1 Year Performance-29.74%-0.33%18.58%8.99% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara1.6375 of 5 stars$2.87-2.2%$8.83+208.3%-32.3%$495.18MN/A-6.66N/ANews CoverageGap DownLGNDLigand Pharmaceuticals4.3412 of 5 stars$106.38+1.8%$146.14+37.4%+16.1%$2.05B$181.49M42.3880Positive NewsHRMYHarmony Biosciences4.7815 of 5 stars$35.65+4.7%$52.33+46.8%+13.1%$2.05B$744.85M16.90200Positive NewsBLTEBelite Bio2.0381 of 5 stars$61.99+1.5%$96.67+55.9%+43.5%$1.97BN/A-55.8510Analyst DowngradeAnalyst RevisionKNSAKiniksa Pharmaceuticals2.9162 of 5 stars$26.84+3.1%$38.80+44.6%+34.7%$1.95B$481.17M-191.70220Positive NewsInsider TradeARWRArrowhead Pharmaceuticals3.51 of 5 stars$13.97+7.2%$41.44+196.7%-38.8%$1.92B$2.50M-2.70400News CoverageAnalyst ForecastAnalyst RevisionGMTXGemini TherapeuticsN/A$44.24-0.1%N/A+56.4%$1.92BN/A-44.2430News CoverageTVTXTravere Therapeutics2.9573 of 5 stars$21.54+7.6%$31.79+47.6%+139.3%$1.91B$273.53M-5.25460Positive NewsGap DownFOLDAmicus Therapeutics3.9848 of 5 stars$6.21+3.8%$16.22+161.2%-35.6%$1.91B$543.14M-34.50480Positive NewsHigh Trading VolumeSUPNSupernus Pharmaceuticals2.6215 of 5 stars$32.15+1.4%$36.00+12.0%+15.0%$1.80B$668.00M30.05580Positive NewsSDGRSchrödinger2.9309 of 5 stars$24.17+1.1%$32.80+35.7%-6.3%$1.77B$207.54M-10.33790News Coverage Related Companies and Tools Related Companies LGND Alternatives HRMY Alternatives BLTE Alternatives KNSA Alternatives ARWR Alternatives GMTX Alternatives TVTX Alternatives FOLD Alternatives SUPN Alternatives SDGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.